Find your next M&A target
Target Asia + Worldwide M&A projects with our guidance on matching, planning, due diligence & implementation.
Search Seller Projects – Europe, Healthcare
Europe: Israel
Israeli Bladder Cancer Treatment Company Seeks to Sell 100% Equity
The Israeli company has developed and commercialized a device for the treatment of Non-muscle Invasive Bladder Cancer (NMIBC). The company’s device has a CE mark and is currently considered by the European Association of Urology (EAU) and the National Institute for Health and Care Excellence (NICE) as one of only few reliable and effective treatments for NMIBC. The company has performed 40,000 treatments in the past 20 years in Europe (incl. UK), Turkey and Israel. The founder and inventor seek to sell the company to concentrate on R&D.
The software-controlled device is minimally invasive and enables disease-free survival following the therapy while maintaining higher bladder preservation rates.
Current annual sales are USD 1 million. Since it is a one-product company, fixed costs remain relatively high (space, accounting, insurance, regulatory). Integration of the product into a large-scale operation is expected to realize cost synergies within the first year of operation.
Europe: Germany
Mass Hands Sanitizer
A machine for hand-sanitizing to be located in public areas (e.g. airports, schools) and events (e.g. fairs, stadiums, etc.) in order to contain and prevent COVID-19 while minimizing waste from empty disinfectant bottles and avoiding the need to recycle them.
Europe: Germany
German autoimmune disease IVD company seeks investment.
The company mainly develops and produces autoimmune disease diagnostic reagent products for early detection, diagnosis and prediction of autoimmune diseases. At present, the company has introduced more than 150 products in the field of diagnostic reagents. Main diagnostics include rheumatology, thrombosis, gastroenterology, vasculitis, thyroid, diabetes, liver disease and lyme disease ELISA detection, immunofluorescence based on cell and tissue slides, and IFA. With more than 200 employees in 20 countries and sales in more than 90 countries.
Europe: Germany
German biological IVD company seeks investment.
The company was founded in Germany and is mainly engaged in the R&D and production of high-end diagnostic system solutions. At present, the global market has covered more than 100 countries and more than 90 kinds of clinical chemical and reaction reagents. The company's revenue in fiscal year 18 / 19 exceeded 60 million euros, of which 80% came from reaction reagents and 20% from testing instruments.
At present, the company has more than 500 employees and more than 200 employees in its headquarters in Germany. The company has R&D institutions in Germany, France, India and China.
At present, the company has more than 500 employees and more than 200 employees in its headquarters in Germany. The company has R&D institutions in Germany, France, India and China.
Europe: Germany
German biomedicine company seeks investment.
The company is a chip laboratory for virus microbial detection, focusing on the timely diagnosis equipment of single molecule sensitivity. Its advantages are
1 single molecule sensitivity: direct single molecule counting without nucleic acid extraction or PCR amplification
2 data analysis network security: safe and convenient desensitization data sharing, convenient for users to build a real-time infectious disease monitoring network
3. Covering large range in single test: up to 120 kinds of viral microorganisms can be detected in a single test, covering almost all viruses, bacteria and parasites endangering human health
4. 15 minutes from the sample to the result: it can respond quickly to the epidemic and formulate treatment and isolation plans
5. Low cost (8 yuan / time / microorganism)
The company has a patented technology, which is the industry's only multi fluorescent labeling coding technology, can detect all dangerous viruses and microorganisms in the human body and make immediate diagnosis at the bedside. It is 40 times cheaper and 20 times faster than the existing scheme. It is predicted that it will occupy 6.3-10.5 billion in infectious disease diagnosis. The company is currently the only molecular diagnostic company that can balance high flux, fast, low cost and accuracy. The company is also a an all-platform company, earning revenue from equipment, consumables, customized development fees and third-party licensing fees. The company is a global innovation company, R&D in Germany and made in China.
1 single molecule sensitivity: direct single molecule counting without nucleic acid extraction or PCR amplification
2 data analysis network security: safe and convenient desensitization data sharing, convenient for users to build a real-time infectious disease monitoring network
3. Covering large range in single test: up to 120 kinds of viral microorganisms can be detected in a single test, covering almost all viruses, bacteria and parasites endangering human health
4. 15 minutes from the sample to the result: it can respond quickly to the epidemic and formulate treatment and isolation plans
5. Low cost (8 yuan / time / microorganism)
The company has a patented technology, which is the industry's only multi fluorescent labeling coding technology, can detect all dangerous viruses and microorganisms in the human body and make immediate diagnosis at the bedside. It is 40 times cheaper and 20 times faster than the existing scheme. It is predicted that it will occupy 6.3-10.5 billion in infectious disease diagnosis. The company is currently the only molecular diagnostic company that can balance high flux, fast, low cost and accuracy. The company is also a an all-platform company, earning revenue from equipment, consumables, customized development fees and third-party licensing fees. The company is a global innovation company, R&D in Germany and made in China.
Europe: Britain
British medical equipment company seeks for investment.
The company is developing a pump that can be implanted directly into the failing heart to treat advanced chronic heart failure. The company aims to apply novel technologies and designs to produce ventricular assist devices (VADs) with obvious advantages over existing methods, including less invasive surgery, reduced thrombosis and control systems optimized for quality of life. The company is raising £ 7.5 million and is now steadily realizing the first implantation of the company's products in the human body in 2021.
Europe: Britain
British clinical biotechnology company seeks for acquisition.
The company is a UK based clinical biotechnology company dedicated to the development of new anti-infectives. Founded in the UK in 1997, it was listed on the London Stock Exchange (LSE) sub market alternative investment market (AIM) in 2017, with a market value of £ 19 million. In 2018, the first new drug for research (IND) was successfully launched in the United States, has obtained fast track qualification, and is starting the planned clinical plan. The pilot drug code named XF-XX has completed a clinical trial funded by the U.S. government. Different from traditional antibiotics, XF-XX shows excellent resistance to a specified bacterial in the laboratory - producing a series of potential low bacterial resistance, which can be used to prevent and treat methicillin resistant Staphylococcus aureus (MRSA) infection. Compared with traditional antibiotics, XF platform has the advantages of killing bacteria quickly, killing bacteria in any growth period and killing bacteria in staphylococcal bacterial biofilm. It is active against all Gram-positive bacteria tested so far and selected Gram-negative bacteria. No bacterial (MRSA) resistance was found. The company continued to strengthen its patent rights and granted XF biofilm patents in Canada in 2018, bringing the total number of patents granted by XF platform to 95.
Europe: Finland
Finish medical R&D company seeks domestic investment or acquisition.
A private company, which is headquartered in Turku, Finland, dedicated to providing innovative diagnostic tools for routine clinical diagnosis and research. Based on its proprietary technology, the company has developed and commercialized the next generation of multifunctional micro detection tools. The advantages of this technology enable it to overcome the performance limitations of the previous generation test in terms of sensitivity, accuracy, ease of use and cost efficiency.
The testing equipment developed by the company has passed ISO 13485:2016 and ISO 9001:2015. This equipment is a cathode electrochemiluminescence instrument that can be used to measure the concentration of components in blood. The technology can be used for animal epidemic prevention. It is convenient and fast to use. The results can be obtained in 5-10 minutes with reliable accuracy. It can be viewed at any time on the independent display screen or mobile phone application on the equipment.
If the matching detection box is used together (the antibody has been wrapped on the chip without calibration), the analyzer can also be used to detect human C-reactive protein (CRP). Results can be displayed in 6-12 minutes from a full blood sample. It can be used to triage patients to reduce uncertainty and avoid unnecessary antibiotic use.
The testing equipment developed by the company has passed ISO 13485:2016 and ISO 9001:2015. This equipment is a cathode electrochemiluminescence instrument that can be used to measure the concentration of components in blood. The technology can be used for animal epidemic prevention. It is convenient and fast to use. The results can be obtained in 5-10 minutes with reliable accuracy. It can be viewed at any time on the independent display screen or mobile phone application on the equipment.
If the matching detection box is used together (the antibody has been wrapped on the chip without calibration), the analyzer can also be used to detect human C-reactive protein (CRP). Results can be displayed in 6-12 minutes from a full blood sample. It can be used to triage patients to reduce uncertainty and avoid unnecessary antibiotic use.
Europe: Britain
British biomedicine company seeks Chinese Partner.
The firm is a Contract Manufacture Organization (CMO) headquartered in the UK, manufacturing and sterile filling bottles for clinical trials and small volume commercial supply. The company was founded in 2011, has sales offices in Boston, the United States. The turnover in 2019 exceeded USD 10 million, and the EBITDA in 2019 exceeded about USD 1.4 million. Core business: sterile production, analysis and microbiological testing, clinical trial services, (CTS): labeling and packaging, release of qualified personnel (QP). The company specializes in production of liquid, lyophilized powder, cytotoxicity, chemical and biopharmaceutical products, including lyophilized powder or liquid, biological agents (peptides, proteins, antibodies, nucleic acids), small molecules and efficient cytotoxins. It has professional facilities: two dust-free rooms with freeze dryer and special cytotoxic and non cytotoxic clean rooms. Test capability: release test, including HPLC, SDS PAGE, ELISA, microbial detection - sterility and endotoxin, etc.
Europe: Britain
British medical equipment company with production in Shenzhen looking for investors to grow their buisiness in China
The company has developed a portfolio of wearable light sources for medical and consumer health applications. There are two distinct product lines. Two products are clinically proven and easy to use for the treatment of specific skin diseases such as non-melanoma skin cancer and acne. The product is manufactured in Shenzhen, and the distribution partner has been appointed in China. It is expected to be provided online in China through T-Mall soon.
Europe: Britain
UK medical equipment manufacturer with clinically proven blood circulation stimulation device seeking investors for expansion to the United States
The company has developed patented neuromuscular electrical stimulation technology and a product that has been clinically proven to increase blood circulation. The product is the size of a watch and is worn behind the knee. It will send a small electric pulse to gently stimulate the common peroneal nerve behind the knee, and then activate the calf and foot muscle pump of the calf to return the blood to the heart. The technique has been developed for the treatment of deep venous thrombosis, advanced wound care, preoperative and postoperative edema reduction, incontinence and athlete rehabilitation. In each clinical field, it improves the prognosis of patients and saves sanitation system resources. The company is raising £ 30-35 million to continue clinical development, product development and marketing in the United States, valued at £ 114 million.
Europe: Britain
Cambridge based biotech R&D firm with unparalleled track record looking for investors
The company is a Cambridge based biotechnology contract research and drug development company, which operates a mixed business model. The revenue is generated through its service business and the development of drug products. The company has an excellent track record in candidate drug delivery. It has a world-class discovery team, and its unparalleled track record shows that it has delivered one candidate drug on behalf of its customers every year in the past six years. Revenue in 2019 was approximately £ 6 million, of which 83% of sales came from a strong growing industrial customer base, which has now become the core of the business.
Enquire for more information about our services, and how we can help solve challenges for your organization
Contact UsOur Clients
Discover our esteemed global clients across diverse sectors. We believe in providing our clients with exceptional service and a commitment to being their partner for growth in Asia.
See what our clients say about us
0
1
2
3